The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells.

, , , ,
doi.org/10.4161/21624011.2014.941737, hdl.handle.net/1765/88237
OncoImmunology
Department of Immunology